40-year-old woman with calcifications detected on baseline screening mammography

 

40-year-old woman with calcifications detected on baseline screening mammography. (Left) Lateral and (right) craniocaudal magnification views show grouped pleomorphic calcifications in right breast (circles). Stereotactic-guided core-needle biopsy yielded radial scar without atypia. Subsequent surgical resection yielded radial scar (i.e., not upstaged).


March 15, 2024 — Screening-detected radial scars without atypia at core-needle biopsy (CNB) have a low upstaging rate to breast cancer of 1.6%, according to the American Journal of Roentgenology (AJR).

“Imaging surveillance rather than surgery is a reasonable approach for radial scars without atypia, particularly for those presenting as calcifications,” wrote coauthor Manisha Bahl, MD, MPH, from Massachusetts General Hospital in Boston.

First delivered as an oral presentation during the 2023 American Roentgen Ray Society (ARRS) Meeting in Honolulu, HI, Dr. Bahl and AJR coauthor Claire Crowley, MB, BCh, BAO, MSc, studied patients who underwent CNB showing radial scar after screening digital breast tomosynthesis (DBT) and digital mammography (DM) (January 1, 2013–December 31, 2020). Patients without surgical excision or at least 2 years of imaging follow-up after CNB were excluded. Rates of upstaging to breast cancer [ductal carcinoma in situ (DCIS) or invasive disease] were compared between radial scars with and without atypia at CNB. Associations of upstaging with patient, imaging, and pathologic variables were explored via statistical testing

Ultimately, among radial scars detected by screening DBT, the upstaging rate to breast cancer for those without atypia was 1.6% (2/129) and for those with atypia was 20.0% (6/30) (p<.001). Of 34 radial scars presenting as calcifications, none was upstaged to cancer.

Bahl and Crowley’s AJR accepted manuscript “also identified features other than atypia that are associated with upstaging risk, including age, a prior diagnosis of breast cancer, and a family history of breast cancer.”

For more information: www.arrs.org


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Breast Imaging

Oct. 6, 2026 — The American College of Radiology (ACR) has recognized Mercy Medical Center’s Tyanna O’Brien Center for ...

Time October 09, 2026
arrow
News | Ultrasound Women's Health

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results ...

Time September 30, 2026
arrow
Subscribe Now